Latest News
Actinium Pharmaceuticals, Inc.
- Actinium Pharmaceuticals initiates study of HER3 targeted radiotherapy in prostate cancer
- Actinium begins phase 1 trial of HER3-targeted cancer therapy By Investing.com
- Actinium Pharmaceuticals presents progress on ATNM-400 clinical and preclinical cancer research
- Actinium Pharmaceuticals, Inc. (ATNM) Presents at European Association of Nuclear Medicine Annual Congress 2026 - Slideshow (NYSE:ATNM) 2026-10-19
- Actinium Pharmaceuticals Announces Inducement Grants to New Employees
- Actinium Pharmaceuticals Appoints Sean Maenpaa Senior Vice President of Business Development
- Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models
- Actinium Pharmaceuticals names Sean Maenpaa business head By Investing.com
- Actinium Pharmaceuticals appoints Sean Maenpaa as SVP to lead business development and strategic partnerships.
- Actinium Pharmaceuticals Appoints Matt David CFO to Support Radiotherapy Pipeline Development
- Actinium appoints Matt David as Chief Financial Officer
- Actinium Pharmaceuticals (ATNM) Edges Higher to $1.10 as Shares Hold Above Key Support - Short Setup Alerts
Headlines from the last 30 days, linking to the original publishers. See all market news →